共 69 条
[1]
Richardson PG(2010)Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma Blood 116 679-86
[2]
Weller E(2017)Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial Lancet 389 519-27
[3]
Lonial S(2020)Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial Blood 136 936-45
[4]
Jakubowiak AJ(2019)With equal access, African American patients have superior survival compared to white patients with multiple myeloma: a VA study Blood 133 2615-8
[5]
Jagannath S(2017)Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States Blood Adv 1 282-7
[6]
Raje NS(2018)Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting Blood Cancer J 8 595-608
[7]
Durie BG(2012)Management of treatment-emergent peripheral neuropathy in multiple myeloma Leukemia 26 119-24
[8]
Hoering A(2021)Recommendations on eliminating racial disparities in multiple myeloma therapies: a step toward achieving equity in healthcare Blood Cancer Disco 2 2294-301
[9]
Abidi MH(2021)The impact of the globalization of cancer clinical trials on the enrollment of Black patients Cancer 127 91-8
[10]
Rajkumar SV(2012)Outcome disparities in multiple myeloma: a SEER-based comparative analysis of ethnic subgroups Br J Haematol 158 e328-e46